Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of the University of British Columbia, its subsidiary’s progress toward the commencement of human trials in Puerto Rico studying lead cannabis strain CTL-X for pain management, its reception of a Health Canada dealer license through subsidiary Cannevert Therapeutics Ltd. (“CTL”) and CTL’s initiation of a cancer research project aimed at assessing the effects of several human cancer cell lines against cannabis strains, among others.
To view the full press release, visit http://cnw.fm/6uipN
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com
More from CannabisNewsBreaks
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com